Aging

[1] GPR109A activation and aging liver.

[2] how useful are monogenic rodent models for the study of human non-alcoholic fatty liver disease?

[3] insulin resistance and chronic hepatitis c

[4] hepatic microcirculatory failure falência microcirculatória hepática

[5] current level of evidence on causal association between hepatitis c virus and type 2 diabetes: a review

[6] esteato-hepatite relacionada ao vírus da hepatite c: perfil clínico-histológico steatohepatitis related to hepatitis c virus: clinical and histological profiles

[7] roux-en y gastric bypass results in long-term remission of hepatocyte apoptosis and hepatic histological features of non-alcoholic steatohepatitis

[8] Hesperidin improves hepatic steatosis, hepatic enzymes, and metabolic and inflammatory parameters in patients with nonalcoholic fatty liver disease: A randomized, placebo-controlled, double-blind clinical trial.

[9] Chronic exposure to tetrabromodiphenyl ether (BDE-47) aggravates hepatic steatosis and liver fibrosis in diet-induced obese mice

[10] Inhibiting Interleukin 11 Signaling Reduces Hepatocyte Death and Liver Fibrosis, Inflammation, and Steatosis in Mouse Models of Nonalcoholic Steatohepatitis

[11] Liver MRI susceptibility-weighted imaging (SWI) compared to T2* mapping in the presence of steatosis and fibrosis

[12] Formononetin alleviates hepatic steatosis by facilitating TFEB-mediated lysosome biogenesis and lipophagy.

[13] Reply to "The Connection between Celiac Disease and Hepatic Steatosis: High Levels of Pigment Epithelium-Derived Factor".

[14] Whole Grain Consumption and Its Effects on Hepatic Steatosis and Liver Enzymes in Patients with Nonalcoholic Fatty Liver Disease: A Randomized Controlled Clinical Trial.

[15] Leptin/adiponectin ratio correlates with hepatic steatosis but not arterial stiffness in nonalcoholic fatty liver disease in Japanese population

[16] Long non-coding RNA (lncRNA) H19 induces hepatic steatosis through activating MLXIPL and mTORC1 networks in hepatocytes.

[17] Ginsenosides reduce body weight and ameliorate hepatic steatosis in high fat diet‑induced obese mice via endoplasmic reticulum stress and p‑STAT3/STAT3 signaling.

[18] Noninvasive assessment of liver steatosis in children: the clinical value of controlled attenuation parameter

[19] Regulation of CD39 expression in ATP-P2Y2R-mediated alcoholic liver steatosis and inflammation

[20] Contamination of organohalogen chemicals and hepatic steatosis in common kingfisher (Alcedo atthis) breeding at a nature reserve near e-waste recycling sites in South China.

[21] Links between donor macrosteatosis, interleukin-33 and complement after liver transplantation.

[22] variability in myosteatosis and insulin resistance induced by high-fat diet in mouse skeletal muscles

[23] trif differentially regulates hepatic steatosis and inflammation/fibrosis in micesummary

[24] effects of 4-nonylphenol on oxidant/antioxidant balance system inducing hepatic steatosis in male rat

[25] efficacy of acetylshikonin in preventing obesity and hepatic steatosis in db/db mice

[26] pnpla3 rs1010023 predisposes chronic hepatitis b to hepatic steatosis but improves insulin resistance and glucose metabolism

[27] grape seed proanthocyanidin rescues rats from steatosis: a comparative and combination study with metformin

[28] rho, a fraction from rhodiola crenulate, ameliorates hepatic steatosis in mice models

[29] the korean mistletoe (viscum album coloratum) extract has an antiobesity effect and protects against hepatic steatosis in mice with high-fat diet-induced obesity

[30] inflammatory mediators of hepatic steatosis

[31] zinc oxide nanoparticle caused plasma metabolomic perturbations correlate with hepatic steatosis

[32] obesity and metabolic phenotypes (metabolically healthy and unhealthy variants) are significantly associated with prevalence of elevated c-reactive protein and hepatic steatosis in a large healthy brazilian population

[33] effect of dietary cocoa tea (camellia ptilophylla) supplementation on high-fat diet-induced obesity, hepatic steatosis, and hyperlipidemia in mice

[34] pparα is required for pparδ action in regulation of body weight and hepatic steatosis in mice

[35] nuciferine downregulates per-arnt-sim kinase expression during its alleviation of lipogenesis and inflammation on oleic acid-induced hepatic steatosis in hepg2 cells

[36] treatment with lobeglitazone attenuates hepatic steatosis in diet-induced obese mice

[37] Viscosol Treatment Ameliorates Insulin-Mediated Regulation of Dyslipidemia, Hepatic Steatosis, and Lipid Metabolism by Targeting PTP1B in Type-2 Diabetic Mice Model.